A plethora of research has demonstrated association of histological measures of anti-tumor immune activity with clinical outcome in multiple cancer types, with the main focus on tumor-infiltrating lymphocytes, particularly CD8+ cytotoxic T cells [5,6,7,8,9,10,11,12,13]. This evidence concerns the gene CD8A and neoplasm.